Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bococizumab for prevention of major cardiovascular events
CTR20160159Phase 3Suspended
- Sponsor
- Pfizer
- Start
- Sep 2016
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of bococizumab in cardiac morbidity, atherosclerotic disease, familial hypercholesterolemia (FH), hypercholesterolemia, sponsored by Pfizer. Started Sep 2016; status: suspended.
02
Drugs
bococizumab
03
Conditions
cardiac morbidityatherosclerotic diseasefamilial hypercholesterolemia (FH)hypercholesterolemia
Beyond the preview
Go deeper on CTR20160159.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20160159.